Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mitotech Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. DEREK JAMES RHOADES is the examiner for this single case. The action is being prosecuted in 1 distinct art unit. With only 1 pending office action and 1 distinct examiner, the company's current activity at the patent office is focused on this one matter. DEREK JAMES RHOADES is the sole official responsible for evaluating the company's current prosecution.
The outcome for this 1 pending office action is entirely in the hands of DEREK JAMES RHOADES. There are no other pending actions to balance the company's prosecution efforts in the Biotechnology & Pharmaceuticals sector. With only 1 distinct art unit involved, the company's current patent office footprint is very narrow. This 1 pending office action represents the entirety of the company's active intellectual property pursuit at this time. The company must ensure its arguments are perfectly tailored to the standards of DEREK JAMES RHOADES to secure its patent rights.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RHOADES, DEREK JAMES | 1 | 72.3% | +16.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19630016 | CRYSTALLINE FORMS OF ANTIOXIDANT COMPOUND | RHOADES, DEREK JAMES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19630016 | CRYSTALLINE FORMS OF ANTIOXIDANT COMPOUND | RHOADES, DEREK JAMES | — |
| Art Unit | Apps |
|---|---|
| 1692 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19630016 | CRYSTALLINE FORMS OF ANTIOXIDANT COMPOUND | RHOADES, DEREK JAMES | 1692 | §102§103§112Other | Non-Final OA | — | Pending | Mar 26, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMitotech Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Derek James Rhoades has the most, with 1 of Mitotech Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
